Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies
Open Access
- 1 January 2026
- journal article
- review article
- Published by Tech Science Press in Oncology Research
- Vol. 34 (7) , 1-10
Abstract
Objectives: Tissue-agnostic oncology personalizes treatments based on shared molecular biomarkers, addressing challenges like assay variability, control-arm rigor, and non-proportional hazards. Integrating efficacy, safety, and resistance factors with consistent estimands is essential for evaluating biomarker-matched therapies across histologies. This review aims to quantify and compare their efficacy and safety, and to identify determinants of resistance, using PRISMA-compliant methods. Methods: We conducted a systematic review and random-effects meta-analysis of 38 studies (15,018 participants), employing dual screening, standardized bias assessment, and evaluations of heterogeneity and small-study effects. Hazard ratios (HRs) with 95% CIs were estimated for time-to-event outcomes, and restricted mean survival times were used when the proportional hazards assumption was violated. Results: Trastuzumab deruxtecan improved objective response rates and extended progression-free survival (PFS) and overall survival (OS) in HER2-positive gastric and gastroesophageal junction cancers and in HER2-low metastatic breast cancer, showing longer response durations. In metastatic colorectal cancer with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR), PD-1 blockade significantly increased PFS and five-year OS despite crossover, with restricted mean survival time gains of about 11 months. In endometrial cancer, dostarlimab combined with chemotherapy improved PFS in both dMMR/MSI-H and mismatch repair–proficient disease and increased OS overall. Encorafenib-based therapies reduced progression and death in BRAF V600E metastatic colorectal cancer. Safety profiles were class-specific: PD-1 inhibitors caused fewer grade 3 or higher adverse events than chemotherapy, whereas trastuzumab deruxtecan was associated with increased interstitial lung disease (ILD) or pneumonitis and higher rates of treatment discontinuation. Conclusion: Biomarker-matched therapies confer significant survival benefits with predictable toxicities. Confidence is strongest for PD-1 inhibitors in MSI-H/dMMR tumors, trastuzumab deruxtecan in HER2-low or HER2-positive cancers, and encorafenib-based regimens in BRAF V600E metastatic colorectal cancer. Implementation should include validated assays (including reconfirmation of HER2 status), prioritize earlier treatment lines where gains are greatest, and require vigilant ILD monitoring. Head-to-head trials and assay standardization, especially for tumor mutational burden, remain priorities.Keywords
This publication has 39 references indexed in Scilit:
- Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyAnnals of Oncology, 2024
- Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Gynecologic Oncology, 2024
- A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastasesAnnals of Oncology, 2024
- Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 studyBreast Cancer, 2024
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialAnnals of Oncology, 2024
- Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2023
- Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC StudyClinical Colorectal Cancer, 2022
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyESMO Open, 2021
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal CancerJAMA Oncology, 2020